Cancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care英文文献资料.docVIP

下载本文档

7
0
约4.41万字
约 11页
2017-05-10 发布于上海
举报
版权申诉

Cancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care英文文献资料.doc

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Cancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care英文文献资料

HindawiPublishingCorporation InternationalJournalofProteomics Volume2012,ArticleID921901,10pages doi:10.1155/2012/921901 ReviewArticle CancerPhenotypeDiagnosisandDrugEf?cacywithin JapaneseHealthCare ToshihideNishimura,1,2,3HarubumiKato, 4 NorihikoIkeda, MakotoKihara, 1 3 MasaharuNomura, 1 YasufumiKato, 1 andGy¨orgyMarko-Varga 1 1 2 DepartmentofSurgery,TokyoMedicalUniversity,6-7-1NishiShinjukuShinjuku-ku,Tokyo160-0023,Japan GraduateSchoolofMedicalScience,YokohamaCityUniversity,3-9FukuuraKanazawa-ku, Yokohama,Kanagawa236-0004,Japan 3 4 MedicalProteoScope,1-6Suehiro-cho,Tsurumi-ku,Yokohamashi,Kanagaewa,230-0045,Japan ThoracicSurgery,NiizashikiChuoGeneralHospital,7-21-chome,Tohoku,Niiza,Saitama352-0001,Japan CorrespondenceshouldbeaddressedtoGy¨orgyMarko-Varga,gyorgy.marko-varga@elmat.lth.se Received9December2011;Accepted28February2012 AcademicEditor:TadashiKondo Copyright?2012ToshihideNishimuraetal.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttribution License,whichpermitsunrestricteduse,distribution,andreproductioninanymedium,providedtheoriginalworkisproperly cited. AnoverviewontargetedpersonalizedmedicineisgivendescribingthedevelopmentsinJapanoflungcancerpatients.These newtargetedtherapieswithnovelpersonalizedmedicinedrugsrequirenewimplementations,inordertofollowandmonitor druge?cacyandoutcome.ExamplesfromIRESSA(Ge?tinib)andTARCEVA(Erlotinib)treatmentsusedinmedicationoflung cancerpatientsarepresented.Lungcancerisoneofthemostcommoncausesofcancermortalityintheworld.Theimportance ofboththequanti?cationofdiseaseprogression,wherediagnostic-relatedbiomarkersarebeingimplemented,inadditionto theactualmeasurementofdisease-speci?cmechanismsrelatingtopathwaysignallingactivationofdisease-progressiveprotein targetsissummarised.Anoutlineisalsopresented,describingchangesandadaptationsinJapan,meetingtherisingcostsand challenges.Today,urgentimplementationofprogramstoaddresstheseneedshasledtoarebuildingoftheentireapproachof medicalevaluationandclinical